| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".
|
Ann Neurol
|
2005
|
24.22
|
|
2
|
A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.
|
N Engl J Med
|
1992
|
4.90
|
|
3
|
Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis.
|
Neurology
|
1997
|
3.68
|
|
4
|
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
|
Lancet
|
2009
|
3.51
|
|
5
|
Clinical practice. Optic neuritis.
|
N Engl J Med
|
2006
|
2.61
|
|
6
|
The neuro-ophthalmology of multiple sclerosis.
|
Lancet Neurol
|
2005
|
2.39
|
|
7
|
Disability in optic neuritis correlates with diffusion tensor-derived directional diffusivities.
|
Neurology
|
2008
|
2.33
|
|
8
|
Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis.
|
Ann Neurol
|
1990
|
1.70
|
|
9
|
Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis.
|
Neurology
|
2009
|
1.52
|
|
10
|
Visual acuity scored by the letter-by-letter or probit methods has lower retest variability than the line assignment method.
|
Eye (Lond)
|
1997
|
1.50
|
|
11
|
Evolving management of optic neuritis and multiple sclerosis.
|
Am J Ophthalmol
|
2005
|
1.48
|
|
12
|
Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis.
|
Neurology
|
2009
|
1.44
|
|
13
|
Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. The Optic Neuritis Study Group.
|
Arch Ophthalmol
|
1997
|
1.37
|
|
14
|
Radial diffusivity in remote optic neuritis discriminates visual outcomes.
|
Neurology
|
2010
|
1.35
|
|
15
|
Contrast sensitivity and other vision tests in the optic neuritis treatment trial.
|
Am J Ophthalmol
|
1996
|
1.31
|
|
16
|
Increased diffusivity in acute multiple sclerosis lesions predicts risk of black hole.
|
Neurology
|
2010
|
1.24
|
|
17
|
Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity.
|
J Neurol Neurosurg Psychiatry
|
2009
|
1.22
|
|
18
|
The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial.
|
Neurology
|
1994
|
1.21
|
|
19
|
Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study.
|
Clin Ther
|
2009
|
1.12
|
|
20
|
4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety.
|
Arch Neurol
|
1994
|
1.05
|
|
21
|
Effects of 4-aminopyridine in patients with multiple sclerosis.
|
J Neurol Sci
|
1983
|
1.02
|
|
22
|
Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a Phase I-II, open-label trial.
|
Clin Ther
|
2009
|
1.01
|
|
23
|
Contrast sensitivity measurements in acute and resolved optic neuritis.
|
Br J Ophthalmol
|
1984
|
1.01
|
|
24
|
Acute and bilateral blindness due to optic neuropathy associated with copper deficiency.
|
Arch Neurol
|
2009
|
0.96
|
|
25
|
Utility of the National Eye Institute VFQ-25 questionnaire in a heterogeneous group of multiple sclerosis patients.
|
Am J Ophthalmol
|
2006
|
0.95
|
|
26
|
Visual symptoms after optic neuritis. Results from the Optic Neuritis Treatment Trial.
|
J Neuroophthalmol
|
1997
|
0.95
|
|
27
|
Self-reported visual dysfunction in multiple sclerosis: new data from the VFQ-25 and development of an MS-specific vision questionnaire.
|
Am J Ophthalmol
|
2002
|
0.95
|
|
28
|
The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study.
|
Ann Neurol
|
1992
|
0.92
|
|
29
|
4-Aminopyridine in multiple sclerosis: prolonged administration.
|
Neurology
|
1991
|
0.85
|
|
30
|
The effects of 4-aminopyridine on motor evoked potentials in multiple sclerosis.
|
J Neurol Sci
|
1998
|
0.83
|
|
31
|
4-Aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study.
|
J Neurol Sci
|
1993
|
0.80
|
|
32
|
Mechanism of action of 4-aminopyridine in the symptomatic treatment of multiple sclerosis.
|
Ann Neurol
|
1995
|
0.76
|
|
33
|
4-Aminopyridine in multiple sclerosis.
|
Ann Neurol
|
1990
|
0.75
|